Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities

Stock Research Monitor: RGNX, RGLS, and ABEO

LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration. For today, WallStEquities.com monitors REGENXBIO Inc. (NASDAQ: RGNX), Regulus Therapeutics Inc. (NASDAQ: RGLS), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO). On Friday, June 29th, 2018, Zacks reported that the NASDAQ Biotechnology Index has lost 1.2% so far in 2018. The report further noted that the performance of biotech bigwigs has been affected by the slowdown in growth of key drugs. Competitive pressure will continue to impact sales. Nevertheless, new drug approvals boosted investor sentiment. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

REGENXBIO

On Tuesday, shares in Rockville, Maryland headquartered REGENXBIO Inc. jumped 4.11%, ending the day at $77.20. The stock recorded a trading volume of 393,376 shares. The Company’s shares have surged 54.25% in the last month, 158.63% over the previous three months, and 276.59% over the past year. The stock is trading above its 50-day and 200-day moving averages by 47.43% and 116.35%, respectively. Moreover, shares of REGENXBIO, which provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease, have a Relative Strength Index (RSI) of 81.16.

On June 12th, 2018, REGENXBIO announced that the US FDA has granted Fast Track designation for RGX-111. RGX-111 is a novel, one-time investigational treatment for Mucopolysaccharidosis Type-I that is designed to deliver the human iduronidase gene directly to the central nervous system using the NAV AAV9 vector. Get the full research report on RGNX for free by clicking below at:

www.wallstequities.com/registration/?symbol=RGNX

Regulus Therapeutics

Shares in San Diego, California headquartered Regulus Therapeutics Inc. ended the day 1.55% higher at $0.72 with a total trading volume of 240,919 shares. In the previous three months, the stock has gained 4.49%. The Company’s shares are trading above their 50-day moving average by 3.16%. Furthermore, shares of Regulus Therapeutics, which engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the US and Europe, have an RSI of 57.48. Today’s complimentary research report on RGLS is accessible at:

www.wallstequities.com/registration/?symbol=RGLS

22nd Century Group

At the close of trading on Tuesday, shares in Williamsville, New York headquartered 22nd Century Group Inc. finished 5.88% higher at $2.70. A total volume of 2.48 million shares was traded, which was above their three months average volume of 1.68 million shares. The stock has advanced 20.54% in the last month, 18.42% over the previous three months, and 56.98% over the past year. The Company’s shares are trading above their 50-day and 200-day moving averages by 21.12% and 4.96%, respectively. Additionally, shares of the Company, which provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding, has an RSI of 67.78.

On June 25th, 2018, 22nd Century Group announced that it was added to the Russell 2000, Russell 3000, and Russell Global indexes on June 22nd, 2018 when Russell FTSE (Russell) reconstituted its US and global equity indexes. Russell added the Company to the Russell Microcap index in 2017. Register now for your free research document on XXII at:

www.wallstequities.com/registration/?symbol=XXII

Abeona Therapeutics

Dallas, Texas-based Abeona Therapeutics Inc.’s shares recorded a trading volume of 278,896 shares at the end of the session. The stock closed the day flat at $16.10. The Company’s shares have advanced 3.70% in the past month, 6.27% in the previous three months, and 143.94% over the past year. The stock is trading below its 200-day moving average by 1.21%. Additionally, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases, have an RSI of 47.08.

On June 05th, 2018, research firm Seaport Global Securities initiated a ‘Buy’ rating on the Company’s stock, with a target price of $29 per share. Click on the link below and see our free report ABEO at:

www.wallstequities.com/registration/?symbol=ABEO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 504479